Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Archives

You are currently viewing the 2010 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: milnacipran hydrochloride

« Back to Dashboard

Milnacipran hydrochloride is the generic ingredient in one branded drug marketed by Cypress Bioscience and is included in one NDA. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for milnacipran hydrochloride. Seven suppliers are listed for this compound.

Summary for Generic Name: milnacipran hydrochloride

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Drug Master File Entries: see list16
Suppliers: see list7

Pharmacology for Ingredient: milnacipran hydrochloride

Clinical Trials for: milnacipran hydrochloride

The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia
Status: Recruiting Condition: Sleep Disorders; Fibromyalgia; Sleep

Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)
Status: Terminated Condition: Irritable Bowel Syndrome

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis
Status: Completed Condition: Arthritis, Rheumatoid

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia
Status: Completed Condition: Fibromyalgia

Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis
Status: Recruiting Condition: Osteoarthritis

Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial
Status: Completed Condition: Fibromyalgia; Neurocognition

A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
Status: Active, not recruiting Condition: Idiopathic Peripheral Neuropathy

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia
Status: Completed Condition: Fibromyalgia

Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran
Status: Recruiting Condition: Back Pain

The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients
Status: Recruiting Condition: Systemic Lupus Erythematosus; Widespread Pain; Fibromyalgia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cypress Bioscience
SAVELLA
milnacipran hydrochloride
TABLET; ORAL022256Jan 14, 2009RXNo<disabled><disabled>
Cypress Bioscience
SAVELLA
milnacipran hydrochloride
TABLET; ORAL022256Jan 14, 2009RXYes<disabled><disabled>
Cypress Bioscience
SAVELLA
milnacipran hydrochloride
TABLET; ORAL022256Jan 14, 2009RXNo6,992,110<disabled><disabled>
Cypress Bioscience
SAVELLA
milnacipran hydrochloride
TABLET; ORAL022256Jan 14, 2009RXYes6,602,911<disabled><disabled>
Cypress Bioscience
SAVELLA
milnacipran hydrochloride
TABLET; ORAL022256Jan 14, 2009RXYes6,992,110<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc